Singapore markets open in 5 hours 53 minutes

Disc Medicine, Inc. (IRON)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
46.62+2.19 (+4.93%)
At close: 04:00PM EDT
48.50 +1.88 (+4.03%)
After hours: 07:21PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close44.43
Open43.97
Bid46.50 x 200
Ask46.79 x 200
Day's range43.97 - 46.64
52-week range25.60 - 77.60
Volume244,231
Avg. volume415,003
Market cap1.153B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Disc Medicine Announces Underwritten Offering of Common Stock

    WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an underwritten offering of 4,944,000 shares of its common stock at a price of $36.00 per share. The aggregate gross proceeds to Disc from this offering are expected to be approximately $178.0

  • GlobeNewswire

    Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

    Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of bitopertin across multiple measures of erythropoietic protoporphyria (EPP) and support development path forwardAdditional data from the ongoing Phase 1b trial of DISC-0974 in myelofibrosis (MF) patients continued to demonstrate greater than 60% hematologic response rates, with durable increases in hemoglobin levels and reductions in transfusion burdenPositive data from initial single-ascending dose (

  • GlobeNewswire

    Disc Medicine to Participate in the Jefferies Global Healthcare Conference

    WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will give a corporate presentation at the Jefferies Global Healthcare Conference on Thursday, June 6th at 1:00 pm ET. A live webcast of the presentation will be available through the investor